Why the study?
Data are limited regarding the use of implantable cardioverter-defibrillators in diverse populations.
Does implantable cardioverter-defibrillator therapy demonstrate differences in cardiovascular outcomes and mortality across distinct sex, race, and age subgroups?
Meta-Analysis (n=7,125)
Yes
Does implantable cardioverter-defibrillator therapy demonstrate differences in cardiovascular outcomes and mortality across distinct sex, race, and age subgroups?
Answers are grounded in this paper and cite their sources.
This meta-analysis highlights a critical underrepresentation of diverse populations in ICD trials, while confirming that based on available data, the mortality benefits of ICD therapy do not significantly differ by sex or race.
BACKGROUND: Data are limited regarding the use of implantable cardioverter-defibrillators (ICDs) in diverse populations. This study explores cardiovascular (CV) outcomes and mortality from ICD randomized controlled trials (RCTs), by sex, race, and age. METHODS: Five electronic databases (PubMed, Emcare, Embase, MEDLINE, and Cumulative Index to Nursing & Allied Health Literature CINAHL) were searched for dates from their inception to July 12, 2021, for RCTs of ICD therapy in adult patients. Data were analyzed for clinical outcomes, including all-cause or CV death, and heart failure hospitalization (HFH). Outcomes data for other non-White, non-Black race groups were often unreported. Most RCTs originated in North America, had male leadership, and were evenly sponsored by industry vs peer-reviewed funding. CONCLUSIONS: Outcomes data are sparse, by sex, race, and age, in current RCTs evaluating ICD therapy. Although ICD patient outcomes did not significantly differ by sex or race, improved data analyses and reporting are needed to determine the relationship between these sociocultural factors and clinical outcomes among distinct ICD patient cohorts.
No takes yet. Share an insight, caveat, or question.
Syed et al. (2021) conducted a meta-analysis in Cardiovascular disease with indication for implantable cardioverter-defibrillator (ICD) (n=7,125). Implantable cardioverter-defibrillator (ICD) vs. Control group (medical therapy, amiodarone, or placebo) and subgroup comparisons (men vs. women, White vs. Black) was evaluated on All-cause death in women compared to men within ICD treatment arms (OR 0.86, 95% CI 0.55-1.35, p=0.51).
Synapse has enriched 10 related papers. Consider them for comparative context: